Why Catalyst Pharmaceuticals (CPRX) Is On Investors’ Radar Now

Catalyst Pharmaceuticals (CPRX) is in focus after reporting record Q4 and full year 2025 results, driven by product revenues from FIRDAPSE and AGAMREE, and issuing 2026 revenue guidance of US$615 million to US$645 million.

Despite record results and new 2026 guidance, Catalyst Pharmaceuticals’ recent share price performance has been fairly muted, with a 3.6% 90 day share price return and an 8.2% one year total shareholder return. Recent earnings and the upcoming BIO Investment & Growth Summit appearance help explain why interest is building, even if short term share price moves have been modest.

If this earnings update has you looking at rare disease and specialty treatments more broadly, it could be a good time to scan our 31 healthcare AI stocks for other ideas in the wider healthcare space.

With record 2025 results, new 2026 revenue guidance of US$615 million to US$645 million, and the share price up 8.2% over the past year, is Catalyst quietly undervalued here, or is the market already pricing in future growth?

Most Popular Narrative: 30.2% Undervalued

The most followed narrative sees Catalyst Pharmaceuticals’ fair value at $34.29 versus the last close of $23.92, and anchors that view on rare disease revenue and margin assumptions.

Broader insurance and payer coverage, evidenced by high FIRDAPSE prescription approval rates (>90%) and strong AGAMREE reimbursement (~85%), supports sustained high market penetration and expands the revenue opportunity, while also aiding margin stability by reducing payer churn and pricing erosion risk.

Read the complete narrative. Read the complete narrative.

Want to see what happens when expanding patient pools, steady margins and future earnings all get wired into one valuation story? The key ingredients behind this fair value call rest on how quickly rare disease diagnoses scale, how much profitability is retained as new products mature, and what kind of earnings multiple that growth could justify. Curious which revenue and margin paths have been plugged in to reach that target price, and how they compare to today’s numbers? The full narrative lays out those projections in detail.

Result: Fair Value of $34.29 (UNDERVALUED)

However, there is still real risk that FIRDAPSE concentration and patent litigation, plus FYCOMPA’s loss of exclusivity, could undercut those upbeat valuation assumptions.

Next Steps

If this mix of optimism and risk feels finely balanced, it is worth checking the numbers yourself and deciding where you stand, starting with 5 key rewards.

Looking for more investment ideas?

If Catalyst has sharpened your interest, do not stop here. Broaden your watchlist with other stock ideas that fit different goals and risk levels.

• Target potential mispricings by scanning our 49 high quality undervalued stocks and see which companies currently look cheap relative to their fundamentals.
• Build a steadier income stream by reviewing 15 dividend fortresses, focused on companies offering higher yields with an emphasis on resilience.
• Prioritise resilience by checking 75 resilient stocks with low risk scores, highlighting businesses that score well on financial strength and overall risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.